Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Faricimab on Renal Function in Patients With Diabetes Mellitus

NCT06929507 is registered in ClinicalTrials.gov with University Hospital, Alexandroupolis as lead sponsor.

NCT NCT06929507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06929507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Faricimab on Renal Function in Patients With Diabetes Mellitus
Lead sponsor
University Hospital, Alexandroupolis
Phase
Not applicable
Overall status
Recruiting
Start date
March 10, 2025
Completion date
March 10, 2027
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme), neovascular age related macular degeneration, renal function disorder